Lanean...
Denosumab for the treatment of osteoporosis
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined w...
Gorde:
| Argitaratua izan da: | Osteoporos Sarcopenia |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Korean Society of Osteoporosis
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6372782/ https://ncbi.nlm.nih.gov/pubmed/30775498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2017.01.002 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|